Eero Poukka
YOU?
Author Swipe
View article: Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024–2025 season: a target trial emulation study based on registry data
Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024–2025 season: a target trial emulation study based on registry data Open
View article: Influenza Epidemiology in Finland During and After the COVID‐19 Pandemic: Surveillance Data Analysis (2019–2024)
Influenza Epidemiology in Finland During and After the COVID‐19 Pandemic: Surveillance Data Analysis (2019–2024) Open
Background The Finnish influenza surveillance system combines traditional virological surveillance and analyses of electronic health records. This paper describes the influenza epidemiology in Finland (population: 5.5 million) during and a…
View article: Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study
Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study Open
In this large multinational study, we found increased risks of GBS within 42 days after Vaxzevria/Covishield vaccination or SARS-CoV-2 infection, and decreased risks after receiving Comirnaty/Tozinameran or CoronaVac/Sinovac COVID-19 vacci…
View article: Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies
Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies Open
In test-negative design studies that use rapid tests to estimate influenza vaccine effectiveness (VE) a common concern is case/control misclassification due to imperfect test sensitivity and specificity. However, an imperfect test can also…
View article: The epidemiology of influenza during the COVID-19 pandemic in Finland -- A summary and interpretation of surveillance data from 2019 to 2024
The epidemiology of influenza during the COVID-19 pandemic in Finland -- A summary and interpretation of surveillance data from 2019 to 2024 Open
View article: Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data
Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data Open
Objective To estimate the effectiveness of vaccination with a monovalent covid-19 mRNA vaccine containing the omicron XBB.1.5 subvariant against severe covid-19 disease in Denmark, Finland, and Sweden. Design Target trial emulation based o…
View article: Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023
Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023 Open
Background Long-term effectiveness data on bivalent COVID-19 boosters are limited. Aim We evaluated the long-term protection of bivalent boosters against severe COVID-19 among ≥ 65-year-olds in Finland. Methods In this register-based cohor…
View article: Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study
Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study Open
In immunocompromised individuals, vaccination with bivalent BA.4-5 or BA.1 booster lowered the risk of Covid-19-related hospitalization and death over a follow-up period of 9 months. The effectiveness was highest during the first months si…
View article: Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study
Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study Open
US Centers for Disease Control and Prevention.
View article: Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness
Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness Open
We assessed the performance of three different multiplex lateral flow assays manufactured by SureScreen, Microprofit and Goldsite which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Between 4 April and 20…
View article: Comparative effectiveness of the monovalent XBB.1.5-containing covid-19 mRNA vaccine across three Nordic countries
Comparative effectiveness of the monovalent XBB.1.5-containing covid-19 mRNA vaccine across three Nordic countries Open
Objective To estimate the effectiveness of vaccination with a monovalent XBB.1.5-containing covid-19 mRNA vaccine against severe covid-19 across three Nordic countries. Design Nationwide cohort studies, using target trial emulation. Settin…
View article: Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study
Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study Open
Objectives To estimate the effectiveness and waning immunity of the bivalent BA.4-5 or BA.1 mRNA booster vaccine against Covid-19-related hospital admission and death in immunocompromised individuals. Design Nationwide cohort analyses usin…
View article: Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness
Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness Open
Background We assessed the performance of three different multiplex lateral flow assays which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Methods Ambulatory patients 6 months and older presenting with t…
View article: Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study
Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study Open
Monitoring the real-life effectiveness of respiratory syncytial virus (RSV) products is of major public health importance. This generic protocol for a test-negative design study aims to address currently envisioned approaches for RSV preve…
View article: Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study
Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study Open
Several immunization products are currently being developed against respiratory syncytial virus (RSV) for children, pregnant females, and older adults, and some products have already received authorization. Therefore, studies to monitor th…
View article: Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study Open
Objective To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19. Design Nationwide cohort analyses, using ta…
View article: Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses Open
Objective To investigate the comparative vaccine effectiveness of heterologous booster schedules (ie, three vaccine doses) compared with primary schedules (two vaccine doses) and with homologous mRNA vaccine booster schedules (three vaccin…
View article: Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023
Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023 Open
Bivalent COVID-19 vaccines were introduced in 2022 but knowledge of their effectiveness against severe COVID-19 outcomes is currently limited. In Finnish register-based cohort analyses, we compared the risk of severe COVID-19 outcomes amon…
View article: Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries
Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries Open
Background Data on the comparative vaccine effectiveness (CVE) of the bivalent mRNA-booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 and BA.1 subvariants are limited. Methods In a period of BA.4-5 subvariants predomin…
View article: Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries
Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries Open
Objective To investigate the effectiveness of heterologous booster schedules with AZD1222 (Oxford-AstraZeneca, referred to as AZD), BNT162b2 (Pfizer-BioNTech, BNT), and mRNA-1273 (Moderna, MOD) vaccines compared with primary schedules and …
View article: High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron Open
Background The elderly are highly vulnerable to severe COVID-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of COVID-19 vaccines. The objective was to estimate vaccine effectiveness (VE) again…
View article: Dawn of the hybrid immunity era in long-term care facilities
Dawn of the hybrid immunity era in long-term care facilities Open
COVID-19 vaccines have saved numerous lives in long-term care facilities around the world by diminishing disease severity. These vaccines have also reduced the risk of COVID-19 outbreaks by decreasing SARS-CoV-2 transmission among resident…
View article: High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron
High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron Open
Background. The elderly are highly vulnerable to severe Covid-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of Covid-19 vaccines. The objective was to estimate vaccine effectiveness (VE) agai…
View article: High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron
High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron Open
Background The elderly are highly vulnerable to severe Covid-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of Covid-19 vaccines. The objective was to estimate vaccine effectiveness (VE) again…
View article: Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021
Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021 Open
View article: Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021
Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021 Open
Prioritisation of elderly people in COVID-19 vaccination campaigns aimed at reducing severe outcomes in this group. Using EU/EEA surveillance and vaccination uptake, we estimated the risk ratio of case, hospitalisation and death notificati…
View article: Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study
Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study Open
Background In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill was prioritized and the interval betw…
View article: Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021
Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021 Open
Recently, Covid-19 vaccine effectiveness has decreased especially against mild disease due to emergence of the Delta variant and waning protection. In this register-based study among healthcare workers in Finland, the vaccine effectiveness…
View article: Detection of SARS-CoV-2 Infection in Gargle, Spit, and Sputum Specimens
Detection of SARS-CoV-2 Infection in Gargle, Spit, and Sputum Specimens Open
Control of the COVID-19 pandemic relies heavily on a test-trace-isolate strategy. The most commonly used specimen for diagnosis of SARS-CoV-2 infection is a nasopharyngeal swab.
View article: 12-15 -vuotiaiden lasten ja nuorten rokottaminen COVID-19 tautia vastaan Suomessa
12-15 -vuotiaiden lasten ja nuorten rokottaminen COVID-19 tautia vastaan Suomessa Open
Koronarokotteet (Covid-19) ovat tällä hetkellä laajasti käytössä yli 16-vuotiailla nuorilla ja aikuisilla. Ensimmäisenä Euroopan komission hyväksymän myyntiluvan 12-15 -vuotiaiden lasten ja nuorten rokottamiselle on saanut BioNTech Pfizeri…